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The bone morphogenetic proteins (BMPs), as members of the transforming growth fac-
tor-β (TGF-β) superfamily, not only control bone formation, but also regulate multiple 
key steps during embryonic development and differentiation. Furthermore, BMPs play 
critical roles in maintaining the homeostasis of the cardiovascular, pulmonary, re-
productive, urogenital, and nervous systems in adult life. Like all members of the TGF-β
superfamily, BMP signaling is mediated through a heteromeric complex of type I and 
type II transmembrane serine/threonine kinase receptors. The subsequent signal 
transduction cascade includes either the canonical Smad-dependent or non-canonical 
Smad-independent pathways. Reflecting the critical function of BMPs, BMP signaling 
is tightly regulated at multiple steps by various mechanisms including extracellular 
endogenous antagonists, neutralizing antibodies/extracellular soluble receptor do-
mains, small molecule inhibitors, cytoplasmic inhibitory Smads, and transcriptional 
co-repressors. Recently, dorsomorphin, the first small molecule inhibitor of BMP sig-
naling, was identified and suggested as a useful tool for dissecting the mechanisms of 
signaling pathways and for developing novel therapeutics for diverse human diseases 
that are related to the BMP signaling pathways. In this article, we discuss various mech-
anisms involved in regulating BMP signaling pathways and their implications for 
urology. 
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INTRODUCTION
 Bone morphogenetic proteins (BMPs) are pleiotropic cyto-
kines and members of the transforming growth factor-β 
(TGF-β) superfamily that include TGF-βs, activins, and 
mullerian inhibitory substance (MIS) [1]. Originally, 
BMPs were isolated from bone extract and were named for 
their effect on cartilage formation and de novo bone for-
mation [2]. During the last two decades, over 20 different 
BMPs have been identified in both vertebrates and in-
vertebrates [3]. 
　More recently, detailed studies have revealed that BMPs 
not only control bone formation but also regulate embry-
onic development and differentiation [4-6]. Indeed, as with 
other members of the TGF-β superfamily, BMPs are im-
portant for gastrulation, mesoderm induction, organo-
genesis, proliferation, and apoptosis of multi-potent cells 
[7]. Besides the effect on embryonic development and dif-
ferentiation, BMPs also play a critical role in homeostasis 
of the cardiovascular, pulmonary, reproductive, urogen-
ital, and nervous systems in mature organisms [8]. Hence, 
BMPs have been linked to certain diseases such as primary 
pulmonary hypertension, fibrodysplasia ossificans pro-
gressiva, and juvenile polyposis syndrome [9-11]. Further-
more, recent reports in oncology revealed that BMPs are 
linked to carcinogenesis, including colorectal, ovarian, and 
lung cancers and melanoma [12-15]. Simultaneously, it 
has been reported that BMP-7 promotes brown adipoge-
nesis. Specifically, Tseng et al reported that BMP-7 ini-
tiates the commitment of mesenchymal progenitor cells to 
a brown adipocyte linage and promotes the differentiation 
of brown preadipocytes [16]. Brown adipose tissue, unlike Korean J Urol 2010;51:511-517
512 Jeong et al
FIG. 1. BMP signal transduction. BMP signaling is transduced by both type I and type II transmembrane serine/threonine kinase 
receptors. BMPs bind to the heteromeric complex of type I and type II receptors. Subsequently, type II receptor phosphorylates type
I receptor, which in turn facilitates phosphorylation of R-Smads (Smad1, 5, and 8). R-Smads directly interact with activated type I
receptor and are released upon phosphorylation. Following the release from the receptor complex, R-Smads complex with Co-Smad
(Smad4) and translocate into the nucleus to modulate the transcription of target genes (canonical BMP-Smad pathway). Independent
of the Smads, BMPs may transduce signal via the MAPK p38 pathway. Endogenous mechanisms of BMP signaling inhibition include
extracellular antagonists such as noggin and chordin, inhibitory Smads (Smad6 and 7), Sno/Ski, and Smurfs. The small molecule 
inhibitor dorsomorphin inhibits type I BMP receptors. –‣: stimuation,  : inhibition, BMPs: bone morphogenetic protein, BMPR: 
BMP receptor, pSmad: phosphorylated Smad, Smurf: Smad ubiquitination regulatory factor, XIAP: human X-chromosome-linked 
inhibitor of apoptosis protein, TAK1: TGFβ-activated kinase 1, NLK: Nemo-like kinase, JNK: Jun kinase, MAPK: mitogen-activated
protein kinase.
white adipose tissue, is essential in energy expenditure 
and may be a potential treatment for obesity [17]. 
　Consistent with the diverse function of BMPs, BMP sig-
naling is mediated through complex signal transduction 
pathways. Currently, over 20 known BMP ligands exert 
their effects through a heteromeric complex of both type I 
and type II transmembrane serine/threonine kinase re-
ceptors [18]. Following binding of the ligands, the combina-
tion of type I and type II receptors initiates a subsequent 
signal transduction cascade by phosphorylating Smads, 
which in turn rapidly move into the nucleus to modulate 
transcription [19]. Alternatively, BMP signaling involves 
Smad-independent pathways that include mitogen-acti-
vated protein kinase (MAPK) p38 [20]. Due to the critical 
role of BMPs, BMP signaling is tightly regulated at multi-
ple steps throughout its signal transduction cascade. 
Among these regulatory mechanisms are endogenous in-
hibitors of BMPs such as noggin, which inhibit BMPs by 
sequestering the ligands [21,22]. In contrast, a small mole-
cule inhibitor of BMPs, dorsomorphin, acts as a specific in-
hibitor of the BMP receptor type I. Because of this specific-
ity, dorsomorphin may be a useful tool for dissecting the 
mechanisms of BMP signaling pathways in many bio-
logical processes as well as for developing novel therapeu-
tics for various human diseases [23].
　In this review, we summarize the current understanding 
of BMP signaling pathways and their regulatory mecha-
nisms in depth, with a particular focus on the negative reg-
ulators, including endogenous and small molecule inhi-
bitors.
COMPLEXITY OF BMP SIGNALING
The basic mechanism of BMP signaling has been well char-
acterized by many investigators (Fig. 1). BMP signaling is 
transduced by a heteromeric complex of type I and type II 
transmembrane serine/threonine kinase receptors [18]. To 
date, three distinct type I receptors, activin receptor-like 
kinase 2 (ALK2), BMP type IA receptor (BMPR-IA/ALK3), 
and BMP type IB receptor (BMPR-IB/ALK6), have been 
identified [24]. Likewise, three type II receptors consisting 
of BMP type II receptor (BMPR-II), activin type IIA re-
ceptor (ActR-IIA), and activin type IIB receptor (ActR-IIB) 
have been described [25]. Both type I and type II receptors 
serve as components for the heteromeric, likely hetero-
tetrameric, receptor complexes to which BMP ligands bind. 
Initially, the ligand binds to type II receptor, which then 
recruits type I receptor. Subsequently, type II receptor Korean J Urol 2010;51:511-517
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TABLE 1. Summary of the inhibitory mechanisms of BMP signal-
ing 
Classification Name Roles
Endogenous antagonists
Noggin Induce neural tissue, 
 Limb development 
BMP-2,-4: high affinity, 
 BMP-7: low affinity
Chordin Induce neural tissue, 
 Limb development
Cerberus Formation of head 
 structure
Caronte Development of left-right 
 symmetry
Follistatin, Gremlin Limb development
Neutralizing antibody/soluble receptors
Myostatin High affinity anti-BMP 
 antibody
Small molecule inhibitors
Dorsomorphin Inhibitor of type I receptors 
 ALK-2,-3,-6
Blocking phosphorylation 
 of Smad 1/5/8
Cytoplasmic inhibitory Smads
I-Smad (-6, -7) Antagonist of R-Smad and 
 Co-Smad signaling
Ski/SnoN Blocking the process of 
 complex formation 
 (R-Smad/Co-Smad)
Smurf Induce degradation of 
 R-Smads by ubiquitination
BMP: bone morphogenetic protein, ALK: activin receptor-like 
kinase, Smurf: Smad ubiquitination regulatory factor
phosphorylates type I receptor, which in turn facilitates a 
subsequent signal transduction cascade by phosphorylat-
ing Smads, a group of intracellular mediators of BMP sig-
naling [19]. 
　Smads involved in BMP signaling are divided into three 
functional groups: 1) receptor-regulated Smads (R-Smads/ 
Smad1, 5, and 8), 2) common-partner Smad (Co-Smad/ 
Smad4), and 3) inhibitory Smads (I-Smads/Smad6 and 7) 
[19]. R-Smads directly interact with activated type I re-
ceptor and are phosphorylated. Activated R-Smads then 
form complexes with the lone Co-Smad. These R-Smads/ 
Co-Smad complexes translocate into the nucleus to modu-
late the transcription of target genes [26]. In this Smad-de-
pendent process, type I receptors appear to be key modu-
lators of the specificity of BMP signaling pathways. For ex-
ample, BMP-6 has a higher affinity for ALK2 receptor, 
through which Smad 1 and 5 are preferentially phosphory-
lated and activated. On the other hand, BMP-7 binds to all 
three type I receptors (ALK2, ALK3, and ALK 6), showing 
different patterns of affinity, and therefore all the R-Smads 
(Smad1, 5, and 8) are likely involved [15]. 
　Although BMPs activate Smads for their signaling and 
it is clear that Smads are critical for BMP signaling path-
ways to modulate target gene transcription, alternative 
pathways different from the Smad pathway have been 
suggested. Like TGF-β and activin, BMP signaling can ac-
tivate the mitogen-activated protein kinase (MAPK) p38 
pathway independent of the Smads [20]. It has been pro-
posed that ligand binding between BMPs and preformed 
heterodimeric receptor complexes leads to the Smad-de-
pendent pathway, whereas induction of receptor com-
plexes by the ligand results in the activation of the alter-
native MAPK p38 pathway [27,28].
REGULATION OF BMP SIGNALING 
Reflecting the critical roles of BMPs, BMP signaling is 
tightly regulated at multiple levels throughout its signal-
ing cascades. Extracellular endogenous antagonists com-
pose the first level of regulation, followed by cytoplasmic 
inhibitory Smads and transcriptional co-repressors (Table 
1).
1. Endogenous antagonists of BMPs
Various endogenous antagonists of BMPs, such as noggin, 
chordin, follistatin, gremlin, ectodin, cerberus, caronte, 
and sclerostin, are secreted into the extracellular space 
[29]. These secreted antagonists directly bind to BMP li-
gands, sequester active BMPs extracellularly, and prevent 
the binding of BMPs to the receptors [30]. The biological 
effects of these endogenous antagonists vary as they re-
strict and terminate BMP signaling. 
　Tight regulation of BMP signaling through the endoge-
nous inhibitors is crucial during early embryogenesis [31]. 
Noggin and chordin induce neural tissue from ectoderm 
and dorsalize ventral mesoderm [32], whereas cerberus 
plays a critical role in the formation of the head [33]. 
Similarly, caronte regulates left-right symmetry [34], 
whereas limb development is controlled by noggin, chor-
din, follistatin, and gremlin [35-39]. The varying effects of 
these endogenous BMP antagonists are likely mediated by 
the differing affinity for BMP subtypes. For example, nog-
gin has high affinity for BMP-2 and BMP-4 but low affinity 
for BMP-7; noggin also competes against gremlin and cer-
berus for BMP-2 [40,41]. 
　The precise regulation of expression of these endogenous 
BMP antagonists remains to be elucidated. Nevertheless, 
a negative feedback look appears to be one important 
mechanism. For example, the increased expression of 
BMP-6 in prostate cancer cells has been associated with 
elevated levels of expression of noggin [42]. Similarly, in 
osteoprogenitor cells, expression of noggin is induced by 
BMP-2, 4, and 6 and the resulting increase in noggin de-
creases the bioactivity of these BMPs in a negative feed-
back loop [43].
2. Cytoplasmic inhibitors of Smads 
Within the cytoplasm, the bioactivity of R-Smads (Smad1, 
5, and 8) and Co-Smad (Smad4) is regulated by various 
inhibitors. These cytoplasmic antagonists of BMP signal-Korean J Urol 2010;51:511-517
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ing include inhibitory Smads (I-Smads/Smad6 and 7), 
Ski/SnoN, and Smurfs (Smad ubiquitination regulatory 
factors) [44,45]. I-Smads compete with R-Smads for the ac-
tivated type I receptor and act as antagonists of R-Smad 
and Co-Smad signaling [46]. Between the two known 
I-Smads, Smad6 preferentially inhibits BMP signaling 
pathways, whereas Smad7 blocks TGF-β superfamily sig-
naling pathways [46]. Mechanistically, I-Smads stably in-
teract with the activated type I receptors, whereas R- 
Smads rapidly dissociate from these receptors. In addition, 
I-Smads, especially Smad6, compete with Co-Smad for the 
activated R-Smads. The physical interaction between 
R-Smads and Co-Smad is also regulated by Ski/SnoN; 
these proteins interfere with the process of complex for-
mation between activated R-Smads and Co-Smad [47]. The 
last known endogenous mechanism of inhibiting BMP sig-
naling involves the ubiquination-induced degradation via 
Smurfs [45].
UROLOGIC IMPLICATIONS OF BMP SIGNALING
In the context of the genitourinary system, BMPs are im-
portant for normal renal development. Although many 
BMPs are expressed during the organogenesis of the meta-
nephric kidney [48], BMP-7 is expressed in both the ure-
teric epithelium and the mesenchyme throughout embry-
onic development [49]. BMP-7 knockout mice have bi-
lateral renal agenesis, suggesting that BMP-7 is absolutely 
required for the proper formation of the kidneys [50]. On 
the other hand, the exact function of BMPs in the adult kid-
ney is still largely unknown. Recently, Mitu and Hirsch-
berg suggested a strong association between BMPs and 
chronic renal disease such as diabetic nephropathy [51]. 
While BMP-7 is heavily expressed by the podocytes, distal 
tubules, and collecting ducts in the adult kidney, ex-
pression of BMP-7 disappears in early fibrogenic renal 
diseases. Interestingly, the exogenous administration or 
transgenic overexpression of BMP-7 reduces renal fibro-
genesis and better preserves nephron function and struc-
tural integrity [51].
　In addition to the development of the genitourinary 
tract, BMPs have also been implicated in the cellular 
growth and progression of malignancy. In an effort to eluci-
date the molecular mechanisms of renal cell carcino-
genesis, Kim et al investigated the potential role of BMP-6 
and its receptors in renal cell carcinoma (RCC) cells [52]. 
They demonstrated that human RCC tissues frequently 
had decreased levels of expression of BMP receptor type II 
(BMP-RII), which was associated with insensitivity to the 
growth-inhibitory effect of BMP-6 in human RCC cells. 
These observations suggest that BMP-6 is a potent in-
hibitor of growth in human RCC cells and that abnormal 
expression of BMP-RII results in a resistance to the 
growth-inhibitory effect of BMP-6. Similarly, Basic-Jukic 
et al demonstrated higher BMP-6 mRNA expression levels 
in clear cell RCC tissue than in benign renal tissue [53]. In 
a more recent report, Blish et al reported that the BMP an-
tagonist sclerostin domain-containing 1 (SOSTDC1) was 
down-regulated in clear cell RCC compared with normal 
kidney tissue [54]. In tissue culture, SOSTDC1 suppressed 
BMP-7-induced phosphorylation of Smad1, -5, and -8 and 
Wnt-3a signaling. These observations suggest that the re-
storation of SOSTDC1 expression may represent a novel 
therapeutic strategy for clear cell RCC because SOSTDC1 
suppresses the proliferation of renal cell carcinoma cells.
　Similar to the RCC studies, Kim et al evaluated the po-
tential role of BMP receptors in bladder transitional cell 
carcinoma (TCC) cells and demonstrated that there was a 
significant association between the loss of BMP-RII ex-
pression and tumor grade [55]. Subsequently, they ob-
served a decreased level of BMP-RII expression in a blad-
der TCC cell line, TSU-Pr1, and an enhanced resistance of 
the growth-inhibitory effect of BMP-6. These results sug-
gest that the overexpression of BMP-RII may restore BMP 
signaling and decrease tumor growth in bladder TCC cells.
　Compared to RCC and bladder TCC, the role of BMPs in 
prostate carcinogenesis has been extensively investigated 
during the last two decades. BMPs were initially im-
plicated in the pathogenesis of osteoblastic metastasis-as-
sociated prostate adenocarcinoma, because BMP-7 was 
frequently overexpressed in the prostate and in metastatic 
bone lesions [56-58]. The precise role of BMP signaling in 
prostate cancer, though, has been controversial. Yuen et 
al reported that increased expression of BMP-6 and de-
creased expression of its inhibitors (noggin and sclerostin) 
promoted the metastatic progression of prostate cancer 
[59]. On the other hand, the expression of BMP-7 tended 
to be lower during the development and progression of pros-
tate cancer, whereas its expression was highest in normal 
prostate glandular tissue [60]. Similarly, Buijs et al re-
ported that BMP-7 can counteract the epithelial-to-mesen-
chymal transition process, suggesting that BMP-7 may be 
a potent inhibitor of prostate cancer bone metastasis in vivo 
[61]. With regard to the role of BMP membrane receptors 
(BMPRs) in prostate cancer, Kim et al observed that the 
loss of expression of BMPRs occurred more frequently in 
high-grade prostate cancer [62]. These observations, taken 
together, suggest that the loss of BMPRs contribute to pros-
tate cancer progression and metastasis by releasing the 
transformed cells from the growth-inhibitory effect of 
BMPs.
BLOCKING BMP SIGNALING
Because overactive BMP signaling is often associated with 
various pathologic conditions, blocking BMPs may be an 
effective therapeutic approach. To this end, macromole-
cules such as neutralizing antibodies are currently being 
developed. These neutralizing antibodies contain a portion 
of the extracellular soluble receptors and recognize various 
BMP ligands as antigenic motifs and prevent the trans-
duction of BMP signaling by neutralizing their activities 
through the antigen-antibody reaction [63].
　Recently, Souza et al reported that the blockade of myo-Korean J Urol 2010;51:511-517
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statin, a member of the TGF-β superfamily and a known 
regulator of muscle mass, resulted in significant muscle 
mass increases [64]. Specifically, adult mice were treated 
with anti-myostatin antibodies, a soluble form of the acti-
vin type IIB receptor (ActR-IIB), designated as ActRIIB-Fc 
(fragment crystallizable), and demonstrated a significant 
increase in muscle mass. Hence, myostatin is a potential 
therapeutic target for the treatment of various muscle- 
wasting diseases such as Duchenne muscular dystrophy 
(DMD), cachexia, and sarcopenia. Similarly, Natsume et 
al investigated the effect of extracellular domain type I re-
ceptor for BMP-2 and 4 by using a silkworm expression sys-
tem and reported that this soluble form of BMP receptor 
(sBMPR) binds to BMPs tightly [65]. Indeed, sBMPR can 
act as a potent BMP antagonist by specifically binding to 
active forms of BMP-2 and 4.
　In addition to the above macromolecules, small molecule 
inhibitors are chemical compounds that can act as selective 
inhibitory regulators of BMP signaling. To date, small mol-
ecule inhibitors have become a useful pharmacological tool 
for dissecting the mechanisms of signaling pathways in 
many biological processes associated with TGF-β signal-
ing. For example, SB-431542 is a small molecule inhibitor 
that is a potent and specific inhibitor of TGF-β type I activin 
receptor-like kinase (ALK) receptors ALK4, ALK5, and 
ALK7 [66]. As such, SB-431542 has the potential to be a 
novel therapeutic agent for diverse human diseases in 
which TGF-β signaling has been implicated [67]. Similarly, 
Lee et al reported that IN-1130 is a relatively nontoxic and 
potent small molecule inhibitor of ALK4, ALK5, and ALK7 
that inhibits TGF-β signaling as well as activin and nodal 
signaling [68]. In prostate cancer cell lines, IN-1130 ex-
hibited an antitumor effect by blocking the immunosup-
pressive effects of the TGF-β signaling.
　Small molecule inhibitors of BMP receptor kinases have 
recently been reported. Using an in vivo screening assay 
based on zebrafish, Yu et al identified a specific small mole-
cule inhibitor of BMP signaling, dorsomorphin [23]. 
Further studies revealed that dorsomorphin inhibits BMP 
type I receptors ALK2, ALK3, and ALK6 and blocks sub-
sequent phosphorylation of Smad1, 5, and 8 and target 
gene transcription [69]. Small molecule inhibitors, such as 
dorsomorphin, are relatively inexpensive, can penetrate 
many cell layers easily, and may be orally bioavailable. 
Thus, these inhibitors may be effective therapies for hu-
man pathologies associated with increased BMP signaling.
CONCLUSIONS
Reflecting their critical roles, BMPs are tightly regulated 
at multiple levels throughout their signal cascades. 
Extracellular endogenous antagonists, such as noggin and 
chordin, directly bind to BMP and sequester the activated 
ligands. In the cytoplasm, there are inhibitory Smads as 
well as Sno/Ski and Smurfs that regulate the R-Smad/ 
Co-Smad interaction and R-Smad degradation, respec-
tively.
　Because the overexpression of BMPs has been im-
plicated in a variety of human diseases including genito-
urinary malignancies, actively inhibiting BMP signaling 
may be an effective therapeutic approach in some patients. 
To this end, neutralizing antibodies and soluble receptor 
domains have been explored. Alternatively, dorsomor-
phin, the first small molecule inhibitor of BMP receptor 
type I, has been reported. As additional small molecule in-
hibitors are identified and characterized, it is likely that 
new therapeutics for various diseases will be discovered. 
Before initiating clinical trials that target BMP signaling 
pathways, the biology of BMPs and the regulatory mecha-
nisms must be clarified. 
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